Lower limbs and caval vein thrombosis;Thromboses veineuses des membres inférieurs et de la veine cave inférieure

EMC - Cardiologie-Angeiologie

Volumn 1, Issue 1, 2004, Pages 80-96

  Leger P ^a   Barcat, D ^a   Boccalon, C ^a   Guilloux, J ^a   Boccalon, H ^a  

^a CHU RANGUEIL   (France)

Author keywords

Anticoagulant; Caval vein; Duplex ultrasound; Lower limb venous thrombosis; Prophylactic treatment; Thrombophilia; Thrombosis

Indexed keywords

EID: 33645734193     PISSN: 17626137     EISSN: 17626137     Source Type: Journal    
DOI: 10.1016/j.emcaa.2003.11.002     Document Type: Short Survey

References (136)

1. Ageno W, Johnson J, Nowacki B, Turpie AG. A computer generated induction system for hospitalized patients starting an oral anticoagulant therapy. Thromb Haemost 2000;83:849-852.
2. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, et al. Three-months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: the Warfarin Optimal Duration Italian Trial (WODIT) study. N Engl J Med 2001;345:165-169.
3. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patward-han NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-938.
4. Anderson FA Jr, Wheeler HB. Venous thromboembolism. Risk factors and prophylaxis. Clin Chest Med 1995;16:235-251.
5. Aschwanden M, Labs KH, Engel H, Schwob A, Jeanneret C, Mueller-Brand J, et al. Acute deep vein thrombosis: early mobilisation does not increase the frequency of pulmonary embolism. Thromb Haemost 2001;85:42-46.
6. Baldt MM, Zontsich T, Stumpften A, Fleischmann D, Schneider B, Minar E, et al. Deep venous thrombosis of the lower extremity: efficacy of spiral CT venography compared with conventional venography in diagnosis. Radiology 1996;200:423-428.
7. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960;1:1309-1312.
8. Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood 2002;100:3470-3478.
9. Bernardi E, Prandoni P, Lensing AW, Agnelli G, Guazzaloca G, Scannapieco G, et al. A D-dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: prospective cohort study. Br Med J 1998;317:1037-1040.
10. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory Bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430-434.
11. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
12. Birdwell BG, Raskob GE, Whitsett TL, Durica SS, Comp P, George JN, et al. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med 1998;128:1-7.
13. Boccalon H, Elias A, Chalé JJ, Cadène A, Gabriel S, for the Vascular Midi-Pyrénées Network Group. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low molecular-weight heparin. Arch Intern Med 2000;160:1769-1773.
14. Bosson JL, Riachi M, Pichot O, Michoud E, Carpentier PH, Franco A. Diameters of acute proximal and distal deep venous thrombosis of the lower limbs. Proposed reference values for ultrasonography. Int Angiol 1998;17:260-267.
15. Bossuyt PM, Prins MH. Does low-molecular-weight heparin reduce the cost of venous thromboembolism treatment? Haemostosis 2000;30(suppl2):136-140.
16. Brandjes DP, Büller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, et al. Randomised trial of the effect of compression stockings in patients with symptomatic proximal vein thrombosis. Lancet 1997;349:759-762.
17. Bressollette L, Nonent M, Oger E, Garcia JF, Larroche P, Guias B, et al. Diagnostic accuracy of compression ultrasonography for the detection of asymptomatic deep venous thrombosis in medical patients. Thromb Haemost 2001;86:529-533.
18. Catalano C, Laghi A, Scipioni A, Sarrantonio A, Coe M, Venosi S, et al. Phlebography with MRI in the study of deep venous thrombosis. Radiol Med 1995;90:38-43.
19. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999;81:165-176.
20. Cazaux V, Gauthier B, Elias A, Lefebvre D, Tredez J, Nguyen F, et al. Predicting daily maintenance of fluindione, an oral anticoagulant drug. Thromb Haemost 1996;75:731-733.
21. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998;158:1641-1647.
22. Cogo A, Bernardi E, Prandoni P, Girolami A, Noventa F. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med 1994;154:164-168.
23. Cronan JJ. Venous duplex US of the lower extremities: effect of duplicated femoral veins. Radiology 1998;206:308-309.
24. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-980.
25. Dauzat M, Laroche JP, Deklunder G, Ayoub J, Quéré I, Lapez FM, et al. Diagnosis of acute lower limb deep venous thrombosis with ultrasound: trends and controversies. J Clin Ultrasound 1997;25:343-358.
26. Decousus H, Liezerovicz A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998;338:409-415.
27. De Moerlose P, Boneu B. Traitement anticoagulant et éducation du patient: une nécessité. Sang Thromb Vaiss 1999;9:647-652.
28. Dunn AS, Schechter C, Gotlin A, Vomvolakis D, Jacobs E, Sacks HS, et al. Outpatient treatment of deep venous thrombosis in diverse intercity patients. Am J Med 2001;110:458-462.
29. Elias A, Fiessinger JN. Maladie thromboembolique veineuse. Collection de Médecine Vasculaire. Paris: Masson; 1995.
30. Eikelbom JW, Quintan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomized trials. Lancet 2001;358:9-15.
31. Eriksson BI, Wille-Jorgensen P, Kälebo P, Mouret P, Rosencher N, Bosch P, et al. A comparison of recombinant hirudin with low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-1335.
32. Eriksson H, Wahlander K, Lundström T, Billing Clason S, Schulman S. Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial. Blood 2002;100:81A [abstract].
33. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-296.
34. Fennerty AG, Dolben J, Thomas P, Backhouse G, Bentley DP, Campbell IA, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J 1984;228:1268-1270.
35. Fennerty AG, Dolben J, Thomas P, Backhouse G, Bentley DP, Campbell IA, et al. A comparison of 3 and 6 weeks anticoagulation in the treatment of venous thromboembolism. Clin Lab Haematol 1987;9:17-21.
36. Fraser JD, Anderson DR. Deep venous thrombosis: recent advances and optimal investigation with US. Radiology 1999;211:9-24.
37. Gates S, Brocklehurst P, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early post-natal period. Cochrane Database Syst Rev 2002;2 CD001689.
38. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson Jr FA, et al. Prevention of venous thromboembolism. Chest 2001;119(suppl1):132S-175S.
39. Ginsberg JS, Kearon C, Douketis J, Turpie AG, Brill Edwards P, Stevens P, et al. The use of D-dimer testing and impedance plethysmography examination in patients with clinical indications of deep vein thrombosis. Arch Intern Med 1997;157:1077-1081.
40. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001;119(suppl1):122S-131S.
41. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry. Lancet 1999;353:1386.
42. Gottlieb RH, Voci SL, Syed L, Shyu C, Fultz PJ, Rubens DJ, et al. Randomized prospective study comparing routine versus selective use of sonography of the complete calf in patients with suspected deep venous thrombosis. AJR Am J Roentgenol 2003;180:241-245.
43. Gottsater A, Berg A, Centergard J, Frennby B, Nirhov N, Nyman U. Clinically suspected pulmonary embolism: is it safe to withhold anticoagulation after a negative spiral CT? Eur Radiol 2001;11:65-72.
44. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-809.
45. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999;130:789-799.
46. Grau E, Tenias JM, Real E, Medrano J, Ferrer R, Pastor E, et al. Home treatment of deep venous thrombosis with low molecular weight heparin: long-term incidence of recurrent venous thromboembolism. Am J Hematol 2001;67:10-14.
47. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999;353:1348-1353.
48. Greer IA. Haemostasis and thrombosis in pregnancy. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone; 1994. p. 987-1015.
49. Groce JB 3rd. Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program. Pharmacotherapy 1998;18:175S-180S.
50. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941.
51. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407-413.
52. Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "the study of men born in 1913". Arch Intern Med 1999;159:1886-1890.
53. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis. Arch Intern Med 2000;160:769-774.
54. Harrison L, McGinnis J, Crowther M, Ginsberg JS, Hirsh J. Assessment of outpatient treatment of deep venous thrombosis with low-molecular-weight heparin. Arch Intern Med 1998;158:2001-2003.
55. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(suppl1):8S-21S.
56. Holmgren KA, Andersson G, Fagrell B, Johnsson H, Ljungberg B, Nilsson E, et al. One-month versus six-months therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985;218:279-284.
57. Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med 1992;116:279-284.
58. Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspect. Haemostasis 1998;28(suppl3):8-16.
59. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997;157:2562-2568.
60. Hull RD, Stein PD, Ghali WA, Cornuz J. Diagnostic algorithms for deep vein thrombosis: work in progress. Am J Med 2002;113:687-688.
61. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, et al. Extended out of-hospital low-molecular weight heparin prophylaxis against deep vein thrombosis in patients after elective hip arthroplasty: systematic review. Ann Intern Med 2001;135:858-869.
62. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613.
63. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288:58-66.
64. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(suppl1):176S-193S.
65. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-983.
66. Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowkedge, controversies, and directions for future research. Blood Rev 2002;16:155-165.
67. Kakkar W, Lawrence D. Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis. Am J Surg 1985;150:54-63.
68. Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001;21:731-738.
69. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907.
70. Kestven PJ, Robinson BJ. Clinical risk factors of venous thrombosis associated with air travel. Aviat Space Environ Med 2001;72:125-128.
71. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al., for the Tasman Study Group. Treatment of venous thrombosis with intravenous unfractioned heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687.
72. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurence of deep vein thrombosis. Lancet 1995;345:152-155.
73. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-462.
74. Laissy JP, Cinqualre A, Loshkajian A, Henry-Feugeas MC, Crestiani B, Riquelme C, et al. Assessment of deep venous thrombosis in the lower limbs and pelvis: MR venography versus duplex Doppler sonography. AJR Am J Roentgenol 1996;167:971-975.
75. Lapostolle F, Surget V, Borron SW, Desmaizieres M, Sordelet D, Lapandry C, et al. Severe pulmonary embolism associated with air travel. N Engl J Med 2001;345:779-783.
76. Léger P, Chabbert V, Otal P, Mailloux G, Lefebvre D, Rousseau H, et al. Exploration des veines des membres inférieurs. Encycl Méd Chir 2000 Elsevier SAS, Paris Radiodiagnostic - Cœur-poumon, 32-225 A-10, 13 p.
77. Léger P. Les cliniques d'anticoagulants. Sang Thromb Vaiss 2003 (sous presse).
78. Léger P, Boccalon C, Vedovatto J, Simonet V, Mallard A, Cambus JP, et al. Education du patient vasculaire, pratique quotidienne en cours d'évaluation. «Pathologie vasculaire: les choix difficiles en pratique quotidienne». Brest: Margaux Orange; 2003.
79. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfrationated heparin in the initial treatment of deep venous thrombosis: an updated meta-analysis. Drugs 1996(suppl 7):30-37.
80. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg JS, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-611.
81. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractioned heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334:677-681.
82. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Thromb Haemost 1999;81:684-689.
83. Meijers JC, Tekelenburg WL, Nouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000;342:696-701.
84. Monagle M, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 2001;119:3445-3705 suppl 1.
85. Nazeyrollas P, Metz D, Jolly D, Maillier B, Jeunesseaux C, Maes D, et al. Use of transthoracic doppler echocardiography combined with clinical and electrocardiographic data to predict acute pulmonary embolism. Eur Heart J 1996;17:779-786.
86. Nordstrom M, Lindblad B, Anderson H, Bergqvist D, Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J 1994;308:891-894.
87. O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, Gent M. Economic evaluation of outpatient treatment with low molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999;159:2298-2304.
88. Oger E, Incidence of venous thromboembolism: a community-based study in Western France. Epi-Getbo Study Group. Groupe d'étude de la thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657-660.
89. O'Shaughnessy DF, Tovey C, Miller AL, O'Neill V, Rana PS, Akbar S, et al. Outpatient management of deep vein thrombosis. J Accid Emerg Med 1999;16:313-314.
90. Ost D, Rozenshtein, Saffran L, Snider A. The negative predictive value of spiral computed tomography for the diagnosis of pulmonary embolism in patients with non diagnostic ventilation-perfusion scans. Am J Med 2001;110:16-21.
91. O'Sullivan EF. Duration of anticoagulant therapy in venous thromboembolism. Med J Aust 1972;2:1104-1107.
92. Partsch H, Kechavarz B, Köhn H, Mostbeck A. The effect of mobilisation of patients during treatment of thromboembolic disorders with low-molecular-weight heparin. Int Angiol 1996;16:189-192.
93. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 1996;348:423-428.
94. Perrier A, Bounameaux H, Morabia A, de Moerloose P, Slosman D, Didier D, et al. Diagnosis of pulmonary embolism by a decision analysis-based strategy including clinical probability, D-dimer levels, and ultrasonography: a management study. Arch Intern Med 1996;156:531-536.
95. Perrier A, Bounameaux H. Cost-effective diagnosis of deep vein thrombosis and pulmonary embolism. Thromb Haemost 2001;86:475-487.
96. Perrier A, Desmarais S, Miron MJ, de Moerloose P, Lepage R, Slosman D, et al. Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet 1999;353:190-195.
97. Perrier A, Miron MJ, Desmarais S, de Moerloose P, Slosman D, Didier D, et al. Using clinical evaluation and lung scan to rule out suspected pulmonary embolism: is it avalid option in patients with normal results of lower-limb venous compression ultrasonography? Arch Intern Med 2000;160:512-516.
98. Pinède L, Ninet J, Duhaut P, Demolombe-Ragué S, Chabaud S, Durieu I, et al., for the investigators of Dotavk Study. A comparison of three and six months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of six and twelve weeks after isolated calf deep vein thrombosis. Circulation 2001;103:2453-2460.
99. Piquet P, Doubine S. Utilisation des héparines de bas poids moléculaire et des antivitamines K en pédiatrie. Sang Thromb Vaiss 2002;14:99-106.
100. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990;263:2753.
101. Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle N, et al. Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular-weight heparins, Tinzaparin and Enoxaparin. Thromb Haemost 1999;81:22-25.
102. Poort RS, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
103. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-1133.
104. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
105. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999;54:265-271.
106. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep vein thrombosis and pulmonary embolism. Lancet 1992;340:873-876.
107. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Elby CS, Dietcher SR, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434.
108. Rodger M, Bredeson C, Wells PS, Beck J, Kearns B, Huebsch LB. Cost effectiveness of LMWH and HNF in treatment of DVT. Can Med Assoc J 1998;159:931-938.
109. Rosengart TK. Anticoagulation self-testing after heart valve replacement. J Heart Valve Dis 2002;11(suppl1):S61-5.
110. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
111. Rosendaal FR. High levels of factor VIII and venous thrombosis. Thromb haemost 2000;83:1-2.
112. Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, et al. Oral contraceptives and venous thrombosis: different contraceptives. Br J Haematol 1997;97:233-238.
113. Rutherford S, Montoro M, McGhee W, Strong T. Thromboembolic disease associated with pregnancy: an 11-year review. Am J Obstet Gynecol 1991;164(2Pt2):286.
114. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-3420.
115. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acute ill medical patients. N Engl J Med 1999;341:793-800.
116. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of anticoagulation trial study group. N Engl J Med 1995;332:1661-1665.
117. Schulman S, Lockner D, Juhlin Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis: a randomised study. Acta Med Scand 1985;217:547-552.
118. Schulman S, Granqvist S, Holmstrom MA. The Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-398.
119. Schwartz RE, Groeger JS, Coit DG. Subcutaneouly implanted central venous access devices in cancer patients: a prospective analysis. Cancer 1997;79:1635-1640.
120. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-593.
121. Spritzer CE, Sostman HD, Wilkes DC, Coleman RE. Deep venous thrombosis: experience with gradient echo MR imaging in 66 patients. Radiology 1990;177:235-241.
122. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-522.
123. Task force on pulmonary embolism, European Society of Cardiology. Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 2000;21:1301-1336.
124. Tick LW, Ton E, van Voorthuizen T, Hovens MM, Leeuwenburgh I, Lobatto S, et al. Practical diagnostic management of patients with clinically suspected deep vein thrombosis by clinical probability test, compression ultrasonography, and D-dimer test. Am J Med 2002;113:630-635.
125. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000;160:2926-2932.
126. Turkstra F, Kuijer PM, van Beek EJR, Brandjes DP, Ten Cate JW, Buller HR. Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med 1997;126:775-781.
127. Turpie AG. Fondaparinux vs Enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-1840.
128. Ulander VM, Stenqvist P, Kaaja R. Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy. Thromb Res 2002;106:13-17.
129. Van den Belt AG, Bossuyt PM, Prins MH, Gallus AS, Buller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis: an economic evaluation. TASMAN Study Group. Thromb Haemost 1998;79:259-263.
130. Van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High-levels of factor IX increase the risk of venous thrombosis. Blood 2000;95:3678-3682.
131. Van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol 1997;47:337-342.
132. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis and the risk for deep vein thrombosis. Blood 2000;95:2855-2859.
133. Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000;83:416-420.
134. Wells PS, Kovacs MJ, Bormanis, Forgie MA, Goudie D, Morrow B, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998;158:1809-1812.
135. White RH, McGahan JP, Daschbach MM, Hartling RP. Diagnosis of deep-vein thrombosis using duplex ultrasound. Ann Intern Med 1989;111:297-303.
136. Wicki J, Perneger TV, Junod A, Bounameaux H, Perrier A. Assessing clinical probability of pulmonary embolism in the emergency ward: a simple score. Arch Intern Med 2001;161:92-97.